Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Valneva SENASDAQ: VALN

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -76.7%

Operating margin was -76.7% in Q1 FY2026, down 64.6 pp from a year earlier. On a trailing-twelve-month basis it was -63.6%, down 30.9 pp year over year. Over 3 fiscal years it narrowed by 15.3 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of -31.0% for the fiscal year ending Dec 2026, up from -46.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-76.7%-18.6 pp QoQ
Last fiscal yearDec 2025
-46.7%-54.6 pp YoY
LTMMar 2026
-63.6%-30.9 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-64.6 pp-5.6 pp+59.0 pp
1 year-54.6 pp+15.7 pp+70.3 pp
3 years-15.3 pp+71.7 pp+87.0 pp
5 years+90.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-46.7%
Year-over-year change
-54.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How VALN compares with its peers on the latest reported figures

  • VALN's LTM Mar 2026 operating margin of -63.6% is the 2nd highest of the 7 companies compared; the peer median is -173.4%.
  • Its year-over-year change of -30.9 pp is the 4th highest of 7, against a peer median of -2.0 pp.
  • Over three fiscal years its change of -15.3 pp compares with a peer median of -162.7 pp.
VALN Competitors Peer median
Operating Margin for VALN and competitors
Company Period LTM level YoY 3-year change
NVAXNovavax, Inc.LTM Mar 2026-11.2% -44.0 pp+90.5 pp
VALNValneva SELTM Mar 2026-63.6% -30.9 pp-15.3 pp
MRNAModerna, Inc.LTM Sep 2026-116.0% +39.9 pp-208.0 pp
IBRXImmunityBio, Inc.LTM Sep 2026-150.2% +165.7 pp+146148.2 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-196.7% -136.0 pp-117.4 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-704.9% +2394.8 pp-734.2 pp
INOInovio Pharmaceuticals, Inc.FY2025-132871.3% -81254.4 pp-130264.0 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding VALN) -173.4%-2.0 pp-162.7 pp

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.